Drug intelligence / Profile preview

perflexane

Development stage: Unknown
Lead developer: Alliance Pharma
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

Perflexane is a fluorinated hydrocarbon (perfluorocarbon) used as a gaseous ultrasound contrast agent. It is administered in the form of microspheres for intravenous injection to enhance echocardiographic imaging. The primary indication is to opacify the left ventricular chamber and improve delineation of the left ventricular endocardial border in patients with suboptimal echocardiograms. Perflexane acts by increasing cell membrane permeability and enhancing ultrasound reflectivity due to its unique physical properties as a gas encapsulated within lipid microspheres. The active product (Imagent) consists of perflexane gas surrounded by a dimyristoylphosphatidylcholine (DMPC) lipid shell[2][3][5].

Brand names: ImagentImavist
Other names: perfluoro-n-hexaneperfluorohexane

Beyond the preview

Go deeper on perflexane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on perflexane.

Explore the full profile